Future Directions for the AIM and EDA Concepts - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 401

6. Garmise RJ, Hickey AJ (2008) Calibration of the Andersen cascade impactor for the charac-
terization of nasal products. J Pharm Sci 97(8):3462-3466
7. Marple VA, Olson BA, Santhanakrishnan K, Roberts DL, Mitchell JP, Hudson-Curtis BL
(2004) Next generation pharmaceutical impactor. Part III: Extension of archival calibration to
15 L/min. J Aerosol Med 17(4):335-343
8. Bowles N, Cahill E, Häberlin B, Jones C, Mett I, Mitchell J, Müller-Walz R, Musa R, Nichols
S, Parkins D, Pettersson G, Preissmann A, Purewal T, Schmelzer C (2007) Application of
quality by design to inhalation products. In: Dalby RN, Byron P, Peart J, Suman JD (eds)
Respiratory drug delivery-Europe 2007. Davis Healthcare International Publishing LLC, River
Grove, IL, pp 61-69
9. US Food and Drug Administration (FDA) (2006) Guidance for industry: quality systems
approach to pharmaceutical CGMP regulations. Rockville, MD. Accessed 26 June 2012 at:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm070337.pdf . Accessed 6 Sep 2012
10. European Medicines Agency (EMA) (2011) EMA-FDA pilot program for parallel assessment
of quality by design applications. EMA/172347/2011, London. Available at: http://www.ema.
europa.eu/docs/en_GB/document_library/Other/2011/03/WC500103621.pdf . Accessed 26
June 2012